Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma

Huazhong University of Science and Technology

Status: Completed

Conditions: Neuroblastoma; 18F-FDG; Wilms Tumor; Hepatoblastoma

Treatments: Other: Telephone follow-up

Study type: Observational

Funder types: Other

Identifiers

NCT06190574

XLan-1218

Details and patient eligibility

About

the primary histologic origin of extracranial solid tumors in children is malignant embryonic cells, including Neuroblastoma (NB) , Hepatoblastoma(HB), and kidney, wilms' tumor(WT). Their main clinical symptoms are large abdominal masses, the most common lymph node metastasis . NB accounts for 15% of childhood cancer deaths, but some low-risk NB can disappear on its own. The International Neuroblastoma Risk Group Staging System (INRGSS) was used to determine Risk before NB treatment, whereas the INRGSS was entirely based on the Neuroblastoma diagnosis, illustrating the importance of imaging in the assessment of NB.18F-FDG is the most commonly used agent in PET imaging of tumor. It can reflect the glucose metabolism of tumor and is widely used in the diagnosis, staging, evaluation of curative effect and prognosis prediction of tumor In this study, the investigators retrospectively analyzed 18F-FDG PET/CT or PET/MRI images from patients with NB, HB, and WT. The investigators sought to assess whether these images provide useful information for diagnosis and prognosis.

Enrollment: 50 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. age < 18 years,
2. have pathological results or definite clinical diagnosis as the gold standard.

Exclusion Criteria：

1. had surgery or chemotherapy before imaging,
2. accompanying other tumors,
3. diabetic patients or patients with fasting blood glucose ≥ 200 mg/dL.